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Purpose: To study the zonal variations in diabetic retinopathy (DR) and associated factors in people with 
known type 2 diabetes mellitus (T2DM) attending large eye care facilities in different regions of India. 
Methods: In this cross‑sectional eye‑care facility‑based study, India was divided into five zones; large 
eye care facilities with a good referral base and offering an entire range of care for patients with DR were 
invited. First‑time T2DM attendees aged ≥18 years were recruited. All subjects received a comprehensive 
systemic and ophthalmic examination. DR and systemic diseases were classified as per the international/
national standards. Findings were compared between the zones and with the national average. Results: 
Fourteen eye‑care facilities (15% public) from five zones participated. In the cohort of 11,173 people, there 
were more males (59%); the average age was above 45 years, and in 57%, DM had been diagnosed more 
than 5 years earlier. Compared with the overall study population, the proportion of people with any DR, 
sight‑threatening DR, and blind were higher in the east zone (42.5%, 95% confidence interval [CI]: 40.2–44.8; 
24.3%, 95% CI 22.3–26.3, and 11.5%, respectively); diabetic macular edema was more frequent in the south 
zone (12.2%, 95% CI 11.2–13.2); people with moderate‑to‑severe visual impairment were more in the west 
zone (32.1%) and higher proportion of people in the south‑central zone had systemic hypertension (56.8%, 
95% CI 54.8–58.9). Conclusion: The zonal variation in DR and related vision loss could be related to variable 
health‑seeking behavior, availability, and confidence in the available services.
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The SPEED (Spectrum of Eye Disease in Diabetes), a 
multicenter, cross‑sectional, observational clinic‑based study, 
was designed to collect data from major eye‑care facilities 
in India to identify the spectrum of eye disorders in people 
with known type‑2 diabetes mellitus (T2DM). Fourteen large 
tertiary eye‑care hospitals (2 public and 12 private, including 
1 diabetes specialty facility) across the country participated in 
the study between August 2016 and January 2017. These 14 
hospitals were located in 5 zones—north, east, west, south, and 
south‑central in 11 cities in India. The study recruited 11,182 
people living with T2DM.
The published data of SPEED include eye disorders in 
people with diabetes, the comorbidities, presence of diabetic 
retinopathy (DR), sight‑threatening diabetic retinopathy (STDR), 
retinal vascular occlusion, and glaucoma.[1‑4] These reports 
showed that the age‑standardized proportion of DR in 
people with T2DM was 32.3% (95% confidence interval [CI]: 
31.4–33.2), and hypertension (48.2%; 95% CI, 47.5–49.4) was 
the most common systemic comorbidity.[1] On multivariate 
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Table 1: Sociodemographic characteristics of respondents
Zone People Gender, n (%) (mean and SD age) DM duration n=11,180 (99.9%)
Female Male ≤5 years n (%) 95% CI >5 years* n (%) 95% CI
South 4368 1871 (42.8) (59.2 ± ) 2497 (57.2) (58.410.6) 1878 (43.1) (41.6‑44.6) 2488 (56.9) (55.4‑58.4)
S. central 2324 891 (38.3) (58.5 1433 (61.7) (59.010.7) 952 (41.0) (39.0‑43.0) 1372 (59.0) (57.0‑61.0)
West 984 369 (37.5) (56.9) 615 (62.5) (59.1 570 (57.9) (54.8‑61.0) 414 (42.1) (39.0‑45.2)
North 1706 808 (47.4) (54.9 898 (52.4) (56.0 788 (46.2) (43.8‑48.6) 918 (53.8) (51.4‑56.2)
East 1800 623 (34.6) (57.1 1177 (65.4) (59.0) 539 (29.9) (27.8‑32.1) 1261 (70.1) (67.9‑72.2)
All zones 11,182 4562 (40.8) (58.4 6620 (59.2) (57.8) 4727 (42.3) (41.4‑43.2) 6453 (57.7) (56.8‑58.6)
*Chi square: 224.4, P<0.001
Table 2: Categorized vision among respondents in different zones
Zone (n) Normal n (%) Early n (%) MSVI n (%) P Blind n (%) P Uncertain/Variable n (%)
South (4368) 2462 (56.3) 793 (18.1) 926 (21.2) 0.261 186 (4.3) 0.374 1 (0.02)
South central (2324) 1145 (49.3) 421 (18.1) 597 (25.7) 0.161 97 (4.2) 0.477 64 (2.7)
West (984) 380 (38.6) 221 (22.5) 316 (32.1) <0.001* 67 (6.8) 0.794 0
North (1706) 998 (58.5) 246 (14.4) 337 (19.7) 0.173 110 (6.5) 0.839 15 (0.9)
East (1800) 957 (53.2) 225 (12.5) 404 (22.4) 0.790 208 (11.5) 0.007* 6 (0.3)
All zones (11,182) 5942 (53.1) 1906 (17.1) 2580 (23.0) ‑ 668 (6.0) ‑ 86 (0.8)
*Significant; MSVI: Moderate‑to‑severe visual impairment; VI: Visual impairment
analysis, a statistically significant association for increased 
risk of DR were male gender (odds ratio [OR] 1.57; 95% CI, 
1.16–2.15), elevated glycated hemoglobin (HbA1c >10%; 
OR 2.39; 95% CI, 1.15–5.22), history of hypertension (OR 
1.42; 95% CI, 1.06–1.88), and duration of diabetes longer 
than 15 years (OR 5.25; 95% CI, 3.01–9.15).[2] Retinal vein 
occlusion (two‑thirds with branch retinal vein occlusion) was 
detected in 3.4% of people,[3] and glaucoma was diagnosed 
in 4.9% (three‑quarters with bilateral and open‑angle) in this 
cohort.[4]
Zonal variation of DM has been reported from India 
(in 2016, DM was highest in the southern states of Kerala 
and Tamil Nadu; least in eastern states).[5,6] But there are no 
reports on similar zonal variation of DR. In this report, we 
reanalyzed the SPEED data per five zones of the country to 
identify any demography differences, comorbidity, and clinical 
presentations.
Methods
Details of the SPEED methodology have already been 
published.[1] In brief, the study included all new patients with 
T2DM attending the retina clinics of 14 participating eye care 
facilities. These centers were selected because of their large 
patient volume and referral base, comprehensive eye care 
facility, and the expertise and ability to treat all types of DR 
and its sequalae. The six zones of India[7] were reconfigured 
into five zones—north, south, east, west, and south‑central, by 
combining the northeast states and the east zone as one entity; 
the two southern states (Andhra Pradesh and Telangana) were 
combined with the central zone (and renamed southcentral 
zone).
All centers had obtained approval from their ethics 
committees, and all adhered to the tenets of the Declaration 
of Helsinki for research involving human subjects. The health 
personnel in each eye care facility collected the data using a 
standard format. All data were stored in a shared repository 
at the Indian Institute of Public Health (IIPH, Public Health 
Foundation of India), Hyderabad, India.
We defined a person as diabetic when the current 
plasma glucose level was >126 mg/dL, or 2‑h post‑load 
glucose was >200 mg/dL, or random plasma glucose 
was >200 mg/dL, or the HbA1c was >6.5%. We defined 
good control of DM when the current plasma glucose 
level was as follows: fasting: <110 mg/dL, 2‑h post‑load 
glucose <140 mg/dL, or HbA1c <5.7%.[8] Hypertension was 
defined as per the Indian norms specified by the National 
Health Mission, as a systolic blood pressure of >140 mmHg 
and diastolic blood pressure of > 90 mmHg.[9] Cardiovascular 
disease (chiefly coronary artery disease) was defined using the 
World Health Organization definition,[10] and diabetic kidney 
disease and neuropathy in people with diabetes was defined 
using the National Institute of Diabetes and Digestive and 
Kidney Disease (NIDDK, NIH, USA) definitions.[11]
Distance presenting vision impairment (VI) was classified 
using the National Program for Control of Blindness and 
Visual Impairment (Government of India) categories defined 
as follows: near‑normal vision: ≥6/9; early VI: 6/12–6/18; 
moderate VI: <6/18–6/60; severe VI: <6/60–3/60; blind <3/60.[12] 
The International Classification of Diabetic Retinopathy was 
used to classify and grade the presence and severity of 
DR.[13] We enquired about six systemic comorbidities among 
individuals with diabetes mellitus. These were hypertension, 
cardiovascular disease (CVD), stroke, diabetic kidney 
disease (DKD), neuropathy, and limb amputation due to 
diabetes.
The collected data included demography, the type and 
duration of DM, and all ocular conditions documented after 
a comprehensive examination of each eye. Only eyes where 
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the fundus could be examined by indirect ophthalmoscopy 
or photographed with a retinal camera were included to 
estimate and classify retinal vascular disease, including DR. 
The following data were analyzed by zone: demographic data, 
systemic comorbidities, and ophthalmic disorders.
Statistical analysis
Stata 14SE for Window (Stata Corp, TX USA) was used for 
statistical analysis. Data were cross‑tabulated, and means and 
standard deviations for continuous variables and percentages 
for categorical variables were compiled. Chi‑square was 
performed to look for the association between zones and 
other variables such as blindness, hypertension, CVD, any 
DR, and STDR in each zone were compared with the averages 
of this cohort and between the zones. For all statistical tests, a 
P value <0.05 was considered statistically significant.
Results
Demography
The 14 study locations included two large public health facilities, 
1 tertiary diabetes care facility with integrated diabetic eye 
care, and 10 non‑government not‑for‑profit eye care facilities. 
These eye care facilities were located in 11 cities—3 in North 
India (Chandigarh—1; Delhi—2), 2 in South Central India 
(both in Hyderabad), 4 in South India (Angamaly, Kerala—1; 
Chennai—2; Madurai, Tamil Nadu—1), 2 in West India (1 each 
in Pune, Maharashtra, and Surat, Gujarat), and 3 in East India 
(1 each in Bhubaneswar, Odisha; Purba Medinipur, Bengal; 
and Guwahati, Assam).
The study recruited 11,182 people with T2DM; all of 
them lived in the zone of India under consideration; the 
lowest recruitment was from the west zone, and 59% were 
male and 41% female. The proportion of females was 
lower than the national average in three zones—south‑
central, east, and west. The average age was 58.2 years 
(±10.6 years; range 39–96 years) [Table 1]. Data on the duration 
of DM were elicited from 11,180 (99.9%) people. Patients living 
in the east zone were more likely to have had diabetes for 
more than 5 years (70.1%), which was higher than the cohort 
average (57.7%), and the difference in duration of DM between 
zones was statistically significant.
In the study, 82% (n = 9169) people were on oral hypoglycemic 
agents (highest in north zone: 88.5%; lowest in east zone: 
67.7%) and 7.7% (n = 865) people were on insulin alone 
(highest in east zone: 17%; lowest in north zone: 2.5%). Diabetes 
were controlled according to the definition of the study in 32.1% 
people (highest in the south‑central zone: 56.8%; lowest in the 
north zone: 7.9%).
On presentation, 6.0% (n = 668) participants were 
blind, and 23% had moderate‑to‑severe visual impairment 
(MSVI; n = 2580) in this cohort. The highest proportion of 
blind people was in the east zone (11.5%), and the highest 
proportion of people with MSVI on presentation was in the 
west zone (32.1%) [Table 2]. The visual acuity measurement 
was either variable/uncertain in patients who had presented 
with an acute red eye (0.8%).
Systemic comorbidities
The most common self‑reported systemic comorbidity in 
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and the least common was stroke (0.4%; n = 49). The highest 
proportions with these comorbidities by zone were as 
follows: hypertension (south‑central zone: 56.8% and east 
zone 56.3%), cardiovascular disease (south zone: 8.5%), stroke 
(south zone: 0.7%), diabetic kidney disease (south zone: 2.0%), 
limb amputation (north and south zone 0.1% each), and 
neuropathy (south zone: 1.1%). Differences between zones 
were statistically significant for hypertension, cardiovascular 
disease, stroke, and diabetic kidney disease [Table 3].
Diabetic retinopathy
We report DR in three categories: any DR, diabetic macula 
edema (DME), and STDR. In this cohort, 32.3% of people 
with DM had any DR (highest in the east zone 42.5%); 9.1% 
had DME (high in south zone 12.2%), and 19.1% people had 
STDR (highest in the east zone, 24.3%) [Table 4]. For each type 
of DR, differences between zones were statistically significant.
Discussion
Diabetes mellitus
The prevalence of DM in India was 5.5% in 1990 and 7.7% 
in 2016.[6] But it is not uniformly distributed between 
the states (India has 28 states and 8 union territories) 
and inside the states. The prevalence of DM in people in 
urban areas is nearly two times of people in the rural area 
(urban: 11.2%; rural: 5.2%).[5] There was a higher prevalence 
of DM in a few southern states (Kerala, Tamil Nadu, and 
Karnataka) and few northern states (Punjab, Delhi) in 1990 
and 2016.[6] Lower prevalence of DM was reported from the 
east and far‑east states of India. But it was also noted that 
significantly greater changes in prevalence from 1990 to 2016 
occurred in the states that had a lower prevalence of DM, such 
as the central, east, and far eastern states of India.[6] In this 
cohort, there were proportionately a greater number of people 
in the east zone with DM of longer than 5‑year duration (70.1%).
Diabetic retinopathy
The prevalence and severity of DR that usually develops 
5–7 years after the onset of T2DM, and around puberty 
in T1DM, depend on many factors, such as the study 
location (rural vs. urban; high‑income vs. low‑income country), 
the study type (population vs. clinic‑based), and the study 
period. The reports of the proportion of people with DR in 
people with DM in India in the last two decades range from 
10.3% to 18.2% in rural areas[14‑16] and from 14.5% to 26.8% in 
urban areas.[17‑20] In the SPEED study, 32.3% of people with 
T2DM attending the eye care facilities had any retinopathy.[2] 
The higher proportion of DR reported in the present study is 
because it was a tertiary hospital‑based study, which is also 
referral institutions, and therefore people needing treatment 
would be utilizing these services. Also, these centers were all 
urban centers, and it is possible that more people from urban 
than rural areas attended the eye care facilities.
DR is likely to increase as the prevalence of diabetes 
is increasing globally and in India. It is estimated that 
approximately one‑third of people with T2DM develop DR 
in 5–7 years after the diagnosis.[21] The 2016 report indicated 
a higher prevalence of DM in certain southern and northern 
Indian states, but bigger shifts in DM prevalence occurred in the 
central, east, and northeast states.[6] However, the proportion of 
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plan (2012–2017). The objectives of NPCDCS are to prevent 
NCDs through advocacy (behavioral and lifestyle changes), 
screening (early diagnosis), capacity building (infrastructure 
development and health personnel training), and periodic 
evaluation (surveillance and monitoring). By March 2016, the 
Government of India had established NCD cells and NCD clinics 
in 298 and 293 districts, respectively, of 718 districts in India.[24] 
In 2016, this was further expanded to a “National Multisectoral 
Action Plan” (NMAP) for Prevention and Control of Common 
Non‑Communicable Diseases (2017–2022) with the engagement 
of 34 ministries, the private sector, and civil society. The NMAP 
has 10 targets and indicators for 2020 and 2025; the ones closely 
related to DM (and DR) are reduction of obesity in general, 
increased physical activity (targets 2020: 5%; 2025: 10%), 
reduction in blood pressure (targets 2020: 10%; 2025: 25%), 
and availability of affordable medicine (targets 2020: 60%; 
2025: 80%).[25]
Early diagnosis and referral
It is also understood that putting together a program and 
providing facilities alone cannot bring about the desired 
results unless there is a concurrent change in people’s behavior 
and the community and trust in the health system. DR is a 
slowly progressing disease. Hence, screening people with or 
at risk of developing DM and appropriate referral is crucial 
in the management.[26] Studies in India and elsewhere have 
demonstrated that medical facilities closer to the residence 
and disease detection combined with definitive treatment, 
such as laser in the appropriate stage of retinopathy, increased 
compliance.[27,28]
Goal—Universal Health Coverage
Good knowledge of the disease is usually associated 
with a positive attitude and good practice.[29] A study 
in East India (Bhubaneswar ) has shown that KAP 
(knowledge‑attitude‑practice) is generally poor in an average 
educated individual.[30] Thus, a more in‑depth inquiry is 
necessary to understand the poor health‑seeking behavior 
of people with DM in East India. A robust health system 
directed explicitly to care of diabetes is required in this region 
to reduce the blindness, and visual impairment secondary to 
DR. Integration of DR screening and management services at 
the district and subdistrict levels is important so that people 
can access timely detection and treatment facilities. At the 
same time, it must be borne in mind that the change in the 
prevalence of DM between 1990 and 2016 was relatively higher 
in the eastern India region (Odisha and Bengal) than the 
South and the South Central zone.[6] Thus, every effort must 
be made to meet the targets proposed by NMAP of reducing 
obesity, reducing hypertension, and increasing physical 
activity. Concurrently a policy change, in addition to the 
ones described in NMAP, is required in the digitalization of 
health information to create a state/national level registry of 
people with diabetes and related health issues so that targeted 
efforts could be made to meet the aspiration of universal 
eye health coverage.[31] It must be understood that such an 
upfront investment in screening is likely to improve patient 
outcomes (and compliance) and would eventually result in 
downstream programmatic savings.[32] However, expanding 
coverage with an increased number of NCD clinics does not 
necessarily guarantee a benefit unless combined with patient 
education, motivation, and behavioral change.
nearly similar period, 2016–2017, did not appear necessarily 
to be at par with the regional prevalence of DM in India; it 
probably reflected the shifting trend of DM prevalence in India.
Zonal variation of DR
The current data showed that the east zone (in this study, 
eye care facilities from Odisha, Bengal, and Assam states) 
reported a higher proportion in any DR and STDR, the 
south zone (in this study Tamil Nadu and Kerala states) 
reported a higher proportion of DME, and north zone 
(in this study Chandigarh and Delhi union territories) 
in DME and STDR compared to other zones. Also, in the 
east zone, there was more number of people with diabetes 
longer than 5 years (70.1% vs. this cohort average of 57.7%), 
a higher proportion of people were blind (11.5% vs. this 
cohort average of 6.0%), a higher proportion of people had 
associated hypertension (56.3% vs. this cohort average of 
48.4%). With a higher proportion of people with diabetes 
living in the south and north zone of India,[6] one could 
probably expect a higher disease burden.
One should expect a lesser disease burden in India’s east 
zone with a lower prevalence of DM. But our analysis showed 
a larger proportion of people were affected in the east zone 
compared to other zones, both in any DR and STDR. The visual 
impairment in people with DR depends on the time and efficacy 
of treatment. In the current analysis, a higher proportion of 
people with DR in the east zone were blind.
O n e  c o u l d  a t t r i b u t e  t h e s e  f i n d i n g s  t o  t h r e e 
hypotheses: (1) the larger age‑standardized percentage 
change of diabetes prevalence between 1990 and 2016[6]; (2), 
the health‑seeking behavior of the people in this region could 
be different; and (3), the health system, particularly for the 
care of non‑communicable diseases, and specifically diabetes, 
could be less advanced/poorly used in the region. In the 
national health ranking in 2019, three study states of the east 
zones (Bengal, Assam, and Odisha) ranked below, at 11, 15, 
and 19, respectively, among India’s 21 large states.[22]
Comparison with the latest national survey in India
The country‑wide population‑based survey, 2015–2019 using 
the Rapid Assessment of Avoidable Blindness 6 (RAAB 6), 
examined 577,776 (42.6% male) people aged 50 years or 
older.[23] The survey showed that 11.8% people had DM (8.0% 
known and 3.8% new). Amongst the people with DM, 16.9% 
people had any DR, 7.0% people had DME, and 3.6% people 
had STDR. Besides, 2.1% people were blind and 13.7% had 
visual impairment. This survey included three districts in 
East India (survey was done in 21 districts), one in Odisha and 
two in West Bengal. In these three districts, the prevalence of 
any DR and STDR was 17.3–20.4% and STDR was 2.0–4.2%, 
respectively. All these figures were lower than in the reported 
cohort for two reasons: (1) more visually impaired people will 
report to a clinic and (2), the RAAB study did not examine 
people under 50 years old.
India program planning for NCD care
In response to the increased burden of non‑communicable 
diseases, the Government of India has created the National 
Program for Prevention and Control of Cancer, Diabetes, 
Cardiovascular Disease, and Stroke (NPCDCS) in 2010, with 
a budget allocation of INR 60.00 billion in the 12th 5‑year 
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Limitations and strengths
This study is not without limitations. The SPEED was a 
facility‑based study, so the findings cannot be generalizable 
to the population. The spread of patients in each zone was 
not uniform; neither was it proportionate to the diabetes 
population. Since all the eye care facilities were in cities or 
larger towns, most patients recruited into this cohort could be 
from urban than rural India. Many with early disease may not 
have reported because of the non‑availability of required care, 
the distance needed to travel, and lack of finance, thus skewing 
the proportion of people with severe visual impairment or 
blindness upward.
The strength of the study lies in the fact that it was a large 
cohort of a patient population with diabetes from all zones of 
the country, and for the first time, a zonal analysis of DR was 
done in India.
Conclusion
DR and related blindness were higher in the eastern zone of 
India than in other zones. These were also proportionately 
higher than the reported prevalence of diabetes mellitus in 
the region. This calls for greater advocacy to improve the 
knowledge‑attitude‑practice of people with diabetes at one end 
and qualitative/quantitative increase in the service provision 
as per India’s national program. A population‑based study 
would provide more precise data that would help in better 
program planning.
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Commentary: Understanding diabetic 
retinopathy trends in India: Lessons 
learnt and future implications
Diabetes has become a major public health problem in India. 
Diabetic retinopathy (DR) is an important cause of avoidable 
blindness. It is imperative to understand that DR has a chronic 
course with a long latent phase. Up to 98% of DR related visual 
impairment can be avoided by early screening and prompt 
management. DR prevalence is increasing at an alarming rate 
in India. The exact epidemiology of DR remains understated 
due to the lack of dilated fundus examinations in routine 
ophthalmic surveys.[1]
The study done by Das et al.[2] brings out the unique zonal 
variation in the prevalence of diabetic retinopathy and its 
complications in patients suffering from type‑2 diabetes 
mellitus who attended different popular healthcare setups 
across India. It is one of the initial studies that have tried to 
highlight the regional variations in DR patient load at various 
urban hospitals across India. They found an overall DR 
prevalence of 32% among diabetic patients which is quite high. 
It may be due to the fact that all enrolment centers were popular 
urban tertiary/regional hospitals. The study also revealed that 
the eastern region of India has a higher proportion of patients 
who suffered from diabetic retinopathy and related blindness 
than any other region despite having a lower prevalence of 
diabetes in the region. A higher rate of DR was also reported 
from studies in Bangladesh as well suggesting a possible role 
of some local environmental factors or genetic influences.[3] 
The increased prevalence of DR related complications in this 
region can also be due to various factors. Poor health‑seeking 
behavior of diabetic patients can be one of the major reasons. 
Unawareness about the fact that diabetes can affect retina 
resulting in ignorance regarding diabetic screening is the major 
factor behind this behavior of patients. In a hospital‑based 
study in Mumbai, it was found that DR prevalence was around 
65% in type‑2 diabetic patients and around 63% of these 
patients were unaware of ocular complications of diabetes 
till they developed vision loss.[4] Another reason can be lack 
of accessible and affordable DR screening and management 
facilities. There are various barriers which can prevent patients 
to access timely health check‑ups. Distance to healthcare 
facility, financial constraints, educational background, and 
associated co‑morbidities make it difficult for the patient 
and their relatives to access healthcare services.[1] There is a 
high prevalence of systemic co‑morbidities in DR patients 
like hypertension, coronary artery disease, stroke, and renal 
diseases, which is also reported in the current study.[2] These 
unique challenges make diabetic patients one of the most 
vulnerable communities in terms of morbidity, mortality, and 
quality of life. We have witnessed this crisis situation during 
the current COVID‑19 pandemic when most of the patients 
coming to vitreo‑retina division of our tertiary eye care facility 
after lockdown were suffering from end‑stage complications 
of diabetes including diabetic retinopathy.[5,6] Most of them 
worsened during lockdown due to lack of timely supervised 
medical care.
The community‑based surveys show less prevalence of DR 
and its complications among diabetics than hospital‑based 
surveys. Recently, R.P. Centre for Ophthalmic Sciences 
conducted the National Diabetic Retinopathy RAAB Survey 
2015‑2019, under the aegis of the Ministry of Health and Family 
Welfare, Govt India. The prevalence of diabetic retinopathy 
among diabetics came out to be 16.9%, a reasonably high 
figure for a RAAB survey.[7] This calls for the formulation 
of an integrated DR screening and management program 
within the existing healthcare system in India.[1] Currently, 
the National Program for Control of Blindness (NPCB) relies 
only on opportunistic screening of DR in high‑risk populations 
in India which emphasizes on early diagnosis, referral, and 
management at every possible point of contact of the patient 
with the healthcare provider.
The ray of hope comes from the experiences of other 
countries in managing DR in their populations. Interestingly, 
the prevalence of diabetic retinopathy and its complications 
has been reportedly reduced in residents of Thailand (a South 
Asian country) from 6.9% in 2014 to 5% in 2019.[8] In 2003, it 
was around 31% which stimulated the authorities to formulate 
Thailand diabetic registry project and universal health coverage 
policy which covered more than 99% of residents by 2013. 
The authors have attributed this policy change which has led 
to improved, accessible, and comprehensive diabetic care to 
be the primary reason for this gradual decrease in DR‑related 
disease burden.
This calls for an increasing need to establish a nationwide 
diabetic retinopathy screening and research network in our 
country. Efforts must also be directed toward building of 
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national registry of diabetic patients.[1] Policy planners should 
be encouraged to focus on patient targeted programs involving 
more of DR outreach screening facilities. In resource‑limited 
Indian settings, every effort must be put to ensure active 
involvement of at least every ophthalmic personnel in the DR 
screening program.[9] To ensure standardized grading and 
management of DR, adequate reforms and innovations must be 
incorporated into the academic curriculum of ophthalmologists 
and optometrists.[10‑12] Incorporating newer technologies like 
smartphone‑based screening, portable non‑mydriatic cameras, 
and artificial intelligence can be a game changer as they will 
increase the scope of DR screening to underserved areas.[13,14]
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